| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Vical Incorporated has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Vical Incorporated | 41 |
$65 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 28-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: VICAL INC | 5 |
$25 |
| 28-Nov-2009 | Standard & Poor's STARS Report |
N/A
| Vical Inc | 8 |
$35 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | VICAL INC (VICL=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | VICAL INC (VICL=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: VICAL INC -- VICL | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ALTUQ , CYTK , IMMU , VITA , TRBN , VICL -- DRUGS | 3 |
$4 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for VICL | 13 |
$25 |
0.03% Nasdaq 
Research Reports
